Monopar Therapeutics Inc. (MNPR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing treatments for cancer. The company has strategically pivoted to prioritize its radiopharmaceutical programs, specifically the Phase 1 imaging trial of MNPR-101-Zr and the late preclinical development of the therapeutic MNPR-101-RIT. Concurrently, the company is winding down its non-radiopharmaceutical programs, including the camsirubicin Phase 1b trial and MNPR-202 preclinical development.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,356,535) | $(4,634,547) |
| Operating Expenses | $3,512,175 | $4,853,253 |
| Research & Development (R&D) | $2,097,088 | $3,248,082 |
| General & Administrative (G&A) | $1,415,087 | $1,605,171 |
| Cash and Cash Equivalents (End of Period) | $6,119,931 | $7,214,757 |
| Investments | $998,840 | $0 |
| Total Current Assets | $7,179,788 | $7,332,513 |
| Accumulated Deficit | $(63,562,752) | $(56,438,568) |
| Net Cash Used in Operating Activities | $(3,332,221) | $(4,372,581) |
| Net Cash Provided by Financing Activities | $3,171,962 | $1,445,976 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $1.34 million compared to the prior year period. R&D expenses dropped by $1.15 million, primarily due to the closure of the Validive clinical trial in March 2023 and reduced manufacturing costs for camsirubicin. These savings were partially offset by increased spending on the MNPR-101 radiopharmaceutical program.
- Financing Activity: The company raised approximately $3.19 million in net proceeds during the six months ended June 30, 2024, through the sale of 2,545,305 shares under its Capital on Demand Sales Agreement. This represents a significant increase in financing cash flow compared to the prior year.
- Investment Portfolio: The company began investing in short-term U.S. Treasury Bills, holding approximately $1.0 million in investments as of June 30, 2024, compared to none in the prior year.
- Stock-Based Compensation: Stock-based compensation expense decreased, contributing to lower G&A expenses, largely due to the full vesting of 2020 grants in late 2023 and no new equity awards issued to the board of directors in 2024.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that current cash resources ($7.1 million in cash, cash equivalents, and investments) are sufficient to fund operations through August 31, 2025. The company anticipates seeking additional capital within the next 12 months to support clinical development.
- Operational Milestones: The Phase 1 imaging and dosimetry trial for MNPR-101-Zr enrolled its first patient on July 9, 2024. The company aims to initiate a Phase 1 therapeutic trial for MNPR-101-RIT in the fourth quarter of 2024.
- Nasdaq Compliance: The company is out of compliance with Nasdaq's minimum bid price requirement ($1.00). To regain compliance, stockholders approved a 1-for-5 reverse stock split, expected to become effective on August 12, 2024. Failure to regain compliance could result in delisting.
- Risks: Key risks include the inability to raise sufficient funds, the uncertainty of clinical trial results, reliance on third-party manufacturers for radiopharmaceuticals, and geopolitical events (e.g., Russia-Ukraine, Israel-Hamas conflicts) affecting supply chains and costs.
Investor Verification Checklist
- Verify the effective date and trading impact of the 1-for-5 reverse stock split scheduled for August 12, 2024.
- Monitor the progress of the MNPR-101-Zr Phase 1 trial enrollment and safety data.
- Assess the timeline and success of future fundraising efforts required to extend the runway beyond August 2025.
- Review the status of the wind-down of the camsirubicin and MNPR-202 programs to ensure no lingering liabilities.
- Confirm the availability and cost of radioisotopes (specifically Actinium-225) under the new supply agreement with NorthStar Medical Radioisotopes.